These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 16883013)

  • 21. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma.
    Tateishi U; Hosono A; Makimoto A; Nakamoto Y; Kaneta T; Fukuda H; Murakami K; Terauchi T; Suga T; Inoue T; Kim EE
    Ann Nucl Med; 2009 Feb; 23(2):155-61. PubMed ID: 19225939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FDG-PET in the detection of residual disease and relapse in patients with Hodgkin's lymphoma. Experience from a Swedish centre.
    Bjurberg M; Gustavsson A; Ohlsson T; Brun E
    Acta Oncol; 2006; 45(6):743-9. PubMed ID: 16938818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer.
    Anjos DA; Etchebehere EC; Ramos CD; Santos AO; Albertotti C; Camargo EE
    J Nucl Med; 2007 May; 48(5):764-70. PubMed ID: 17475965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PET and PET/CT in pediatric oncology.
    Jadvar H; Connolly LP; Fahey FH; Shulkin BL
    Semin Nucl Med; 2007 Sep; 37(5):316-31. PubMed ID: 17707239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 18-F FDG-PET in the staging of lymphocyte-predominant Hodgkin's disease.
    Ansquer C; Hervouët T; Devillers A; de Guibert S; Gastinne T; Le Gouill S; Garin E; Moreau A; Kraeber-Bodéré F; Lamy T
    Haematologica; 2008 Jan; 93(1):128-31. PubMed ID: 18166797
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasmablastic lymphoma of the oral cavity in an HIV-positive patient: staging with 18F-FDG PET/CT.
    Makis W; Ciarallo A; Lisbona R
    Acta Radiol; 2011 Nov; 52(9):970-2. PubMed ID: 21911839
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma.
    Shen YY; Kao A; Yen RF
    Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New developments in staging and follow-up of patients with Hodgkin's lymphoma.
    van Spronsen DJ; Veldhuis GJ
    Neth J Med; 2003 Sep; 61(9):278-84. PubMed ID: 14692440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Non-Hodgkin's lymphoma of the bone and the liver without lymphadenopathy revealed on FDG-PET/CT.
    Cheng G; Servaes S; Chamroonrat W; Li J; Zhuang H
    Clin Imaging; 2010; 34(6):476-9. PubMed ID: 21092880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy?
    Hutchings M
    Hematol Oncol Clin North Am; 2014 Feb; 28(1):87-103. PubMed ID: 24287070
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification.
    Tsukamoto N; Kojima M; Hasegawa M; Oriuchi N; Matsushima T; Yokohama A; Saitoh T; Handa H; Endo K; Murakami H
    Cancer; 2007 Aug; 110(3):652-9. PubMed ID: 17582800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imaging of non-Hodgkin lymphomas: diagnosis and response-adapted strategies.
    El-Galaly TC; Hutchings M
    Cancer Treat Res; 2015; 165():125-46. PubMed ID: 25655608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of FDG-PET imaging in the management of lymphoma.
    Kostakoglu L; Leonard JP; Coleman M; Goldsmith SJ
    Clin Adv Hematol Oncol; 2004 Feb; 2(2):115-21. PubMed ID: 16163171
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of FDG-PET in malignant lymphoma.
    Becherer A; Jaeger U; Szabo M; Kletter K
    Q J Nucl Med; 2003 Mar; 47(1):14-21. PubMed ID: 12714950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FDG-PET imaging for Hodgkin lymphoma: current use and future applications.
    Kostakoglu L; Evens AM
    Clin Adv Hematol Oncol; 2014 Jan; 12(1):20-35. PubMed ID: 25000313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Musculoskeletal lymphomas].
    Ludwig K
    Radiologe; 2002 Dec; 42(12):988-92. PubMed ID: 12486552
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hodgkin's and non-Hodgkin's lymphomas.
    Rademaker J
    Radiol Clin North Am; 2007 Jan; 45(1):69-83. PubMed ID: 17157624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 18F-FDG PET is superior to 67Ga SPECT in the staging of non-Hodgkin's lymphoma.
    Yamamoto F; Tsukamoto E; Nakada K; Takei T; Zhao S; Asaka M; Tamaki N
    Ann Nucl Med; 2004 Sep; 18(6):519-26. PubMed ID: 15515753
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 18FDG PET versus high-dose 67Ga scintigraphy for restaging and treatment follow-up of lymphoma patients.
    Van Den Bossche B; Lambert B; De Winter F; Kolindou A; Dierckx RA; Noens L; Van De Wiele C
    Nucl Med Commun; 2002 Nov; 23(11):1079-83. PubMed ID: 12411836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.